Literature DB >> 12555659

Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo.

Martin H Holtmann1, Eleni Douni, Michael Schütz, Geraldine Zeller, Jonas Mudter, Hans-Anton Lehr, Jeanette Gerspach, Peter Scheurich, Peter R Galle, George Kollias, Markus F Neurath.   

Abstract

Tumor necrosis factor (TNF) plays a pivotal role in the pathogenesis of Crohn's disease (CD). However, little is known about the role of TNF receptors (TNF-R) in this disease. Here, we found that TNF-R2 (in contrast to TNF-R1) was significantly up-regulated on lamina propria and peripheral blood T cells in CD compared to control patients. To directly test the functional role of TNF-R2 in Th1-mediated experimental colitis in vivo, we took advantage of transgenic animals overexpressing TNF-R2 in T cells. Reconstitution of SCID mice with CD4+ CD62L+ T cells from TNF-R2 transgenic mice led to an earlier wasting syndrome, a more severe colitis and augmented Th1 cytokine production than reconstitution with cells from wild-type littermates. In addition, TUNEL staining revealed a significantly decreased apoptosis rate of lamina propria mononuclear cells in mice reconstituted with TNF-R2 transgenic T cells compared to mice reconstituted with wild-type T cells. In summary, our data suggest a critical regulatory role of TNF-R2 signaling for disease exacerbation in Th1-mediated chronic colitis. Taken together with the increased expression of TNF-R2 in CD, selective targeting of TNF-R2 signaling thus emerges as a potentially novel approach to the treatment of CD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555659     DOI: 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

2.  Transplanting the genetic susceptibility to Crohn's disease.

Authors:  M H Holtmann; M F Neurath
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 3.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

Review 4.  Cytokines in inflammatory bowel disease.

Authors:  Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

Review 5.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

6.  The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.

Authors:  Minoru Nakai; Kaori Sudo; Yasuhiro Yamada; Yasushi Kojima; Tomohiro Kato; Kuniaki Saito; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

7.  Colitogenic role of tumour necrosis factor (TNF) receptors in trinitrobenzene sulphonic acid colitis: TNF-R1 ablation does not affect systemic inflammatory response.

Authors:  Y Yang; H Wang; Y Dou; Y Wang; G Han; Renxi Wang; L Wang; R Guo; H Xiao; X Li; B Shen; Y Shi; G Chen; Y Li
Journal:  Clin Exp Immunol       Date:  2011-06-14       Impact factor: 4.330

8.  TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis.

Authors:  Mario Noti; Nadia Corazza; Christoph Mueller; Barbara Berger; Thomas Brunner
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

9.  Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis.

Authors:  Marina Tiumentseva; Vera Morozova; Aleksandr Zakabunin; Denis Korobko; Nadezhda Malkova; Maksim Filipenko; Nina Tikunova
Journal:  Immunogenetics       Date:  2016-01-07       Impact factor: 2.846

10.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

Authors:  Imke Tiede; Gerhard Fritz; Susanne Strand; Daniela Poppe; Radovan Dvorsky; Dennis Strand; Hans Anton Lehr; Stefan Wirtz; Christoph Becker; Raja Atreya; Jonas Mudter; Kai Hildner; Brigitte Bartsch; Martin Holtmann; Richard Blumberg; Henning Walczak; Heiko Iven; Peter R Galle; Mohammad Reza Ahmadian; Markus F Neurath
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.